Francisco J. Esteva: The role of palbociclib in improving outcomes for patients with metastatic breast cancer
Francisco J. Esteva, Chief of Division of Hematology and Medical Oncology at Lenox Hill Hospital, shared on LinkedIn:
“The PATINA trial explored the role of palbociclib (a CDK4/6 inhibitor) in improving outcomes for patients with metastatic breast cancer (MBC) that is ER+/HER2+.
The study included 518 patients who received initial treatment with THP (taxane, trastuzumab, pertuzumab) for 6 cycles. Patients with disease control were then randomized to:
• HP + endocrine therapy (standard care)
• HP + endocrine therapy + palbociclib
The trial evaluated whether the addition of palbociclib enhanced the efficacy of HER2-targeted therapy and endocrine treatment.
The results, presented at SABCS24, by Dr. Otto Metzger at DFCI offer insights into combining targeted and endocrine therapies in this patient population.
Would this combination be considered standard of care in HER2-positive metastatic breast cancer? “
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023